Bayer Faces a Three-Front Battle: Tariffs, Pharma Litigation, and a $7.25 Billion Settlement
Published on 07/01/2026 at 19:15 | Redaktion boerse-global.de
Bayer shares have staged a remarkable recovery, climbing 39% over the past 30 days to trade at €48.93 — just a hair below their 52-week high of €49.93 set on 17 February. The relative strength index has pushed past 80, flashing an overbought signal even as the company navigates a maze of legal, commercial, and regulatory pressures.
Yet beneath the rally, the German life-sciences group is fighting on three distinct fronts: a trade war triggered by its own Monsanto subsidiary, a high-stakes patent battle with Johnson & Johnson over a blockbuster cancer drug, and a looming $7.25 billion settlement that could either draw a line under its legacy liabilities or deepen the financial hole.
Farmers Cry Foul Over Monsanto’s Anti-Dumping Petition
Monsanto and its affiliate Ruevon LLC have petitioned the US International Trade Commission to slap steep anti-dumping duties on Chinese glyphosate, alleging the herbicide is being sold in America at below fair-market value. The requested tariffs range from 68.9% to a staggering 446.47%.
The move has infuriated US farm groups. Bayer/Monsanto is the sole domestic producer of glyphosate, controlling roughly 60% of the American market according to Progressive Farmer. Higher import levies would further cement that dominance — but at the cost of alienating the very farmers who rely on affordable supplies.
Should investors sell immediately? Or is it worth buying Bayer?
Jed Bower, president of the National Corn Growers Association, accused Bayer of breaking faith with the agricultural community. Farmers, he noted, had stood “hand in hand” with the company during years of glyphosate litigation. Now, after four years of soaring costs for chemicals, seed, and fertilizer, a new layer of import duties threatens to squeeze their access to essential inputs even further.
The timing is particularly awkward. Only in late June did Bayer notch a landmark victory at the US Supreme Court, which ruled that consumers cannot sue the company under state law for failing to warn about cancer risks on Roundup labels — because federal regulators never required such a warning. The decision was hailed as a major win and sent the stock sharply higher. The tariff petition risks poisoning that goodwill, especially among the farmers who have been Bayer’s most vocal allies.
Taking on Johnson & Johnson Over Cancer Drug Data
On the pharma side, Bayer has launched a legal offensive of its own. The company sued Johnson & Johnson in New York, accusing its rival of running misleading advertisements for the prostate-cancer drug Erleada. J&J claims in a campaign that Erleada reduces the risk of death by 51% more than Bayer’s Nubeqa. Bayer says the data is scientifically flawed.
The case escalated in mid-June, with Bayer demanding damages and an immediate halt to the advertising. A court has acknowledged methodological weaknesses in J&J’s claims, but Bayer lacks the raw trial data to prove its case — J&J has yet to hand over the full study results.
The financial stakes are enormous. Nubeqa is one of Bayer’s fastest-growing products, with sales surging 57% last year to €2.4 billion. More than 200,000 patients worldwide now receive the drug. Any erosion of its market position would hurt an already strained pharmaceutical pipeline.
Pipeline Crunch and AI Ambitions
Time is also pressing for Bayer’s next-generation stroke treatment, Asundexian. The European Medicines Agency is already reviewing the drug, which promises to cut the risk of recurrent ischemic strokes by 26% in high-risk patients. Both China and the US have agreed to accelerated reviews.
The urgency is clear: patents for Bayer’s legacy blockbuster Xarelto are expiring soon, and Asundexian must fill that revenue gap. To speed future discovery, Bayer has partnered with Iambic Therapeutics, using the startup’s AI platform to identify new drug candidates faster — an attempt to shorten the traditional, multibillion-dollar research cycle.
Bayer at a turning point? This analysis reveals what investors need to know now.
Debt and the July 9 Settlement Deadline
All these commercial battles are unfolding against a strained balance sheet. Net financial debt stood at €32.5 billion at the end of March, up 9% since the start of the year. The main culprit: costly legal settlements. Roughly €2 billion has already flowed out to resolve PCB and glyphosate claims, and the board expects total cash outflows of about €5 billion for the full year 2026. Free cash flow is set to turn deeply negative.
The next big date is 9 July, when a court will rule on the final approval of a $7.25 billion settlement package. Bayer hopes that deal will draw a conclusive line under a large chunk of its legacy litigation — but it will also eat further into cash reserves.
For now, the stock’s rally reflects genuine progress: a Supreme Court win, a strong pharma pipeline, and aggressive moves to defend market share. But the company is walking a tightrope between protecting its own interests and maintaining the trust of farmers, patients, and investors. The ITC has yet to rule on the glyphosate tariffs, and the J&J lawsuit is far from resolved. How Bayer balances these competing pressures over the coming months will determine whether the recent share-price surge has staying power or proves to be a short-lived sugar rush.
Ad
Bayer Stock: New Analysis - 1 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
